https://biopharmaperspective.com/2026/10/06/vaxcytes-vax-31-meets-phase-3-endpoints-versus-prevnar-20-and-capvaxive/ 2026-10-06T05:33:48Z Biopharma Perspective en Vaxcyte’s VAX-31 Meets Phase 3 Endpoints Versus Prevnar 20 and Capvaxive 2026-10-06T05:33:47Z Blog https://biopharmaperspective.com/2026/10/05/eli-lillys-jaypirca-wins-fda-approval-for-first-line-cll-sll/ 2026-10-05T05:27:23Z Biopharma Perspective en Eli Lilly’s Jaypirca Wins FDA Approval for First-Line CLL/SLL 2026-10-05T05:27:21Z Blog